Purpose:
In Japan, the death rate from the liver cancer is increasing year by year and
now the statistics show that it is ranked the third for the man and the fourth
for the women out of all liver cancer.
The occurrence rate for the liver cancer from the hepatitis type C has three
times more than that of the hepatitis type B. At present, the Interferon is
the effective medicine for the hepatitis type C, however, 70 % of Japanese
is sero-type 1 and 30% for sero-type 11 and the Interferon is not so effective
for the sero-type 1 which has 70% shares in Japan.
Even at the hospital which is known as the leading edge treatment for
the hepatitis type C just put the medicine of strong SNMC and URSO without
any reason for the patients who are not effective with the Interferon.
With these backgrounds, we have started to give the Yojyo Hen Shi Ko (health
foods) to the patients to study its effect since several years ago.
Objective and clinical cases:
We have given the Yojyo Hen Shi Ko (Denshichi, Denshichi-Tochusei, Ousei, Licorice)
to 195 cases including 180 cases (92%) of viral liver diseases, 7 cases (4%)
for alcoholic liver diseases, 6 cases (3%) for fatty liver, and 2 cases for
auto immune diseases (1%) from April 1998 to June 2001 and examined and observed
the progress of the liver function before and after the dosages.
The following items are measured.
1. Biochemorphic examination for the liver function
2. Blood test
3. Virus volume (HBV-DNA)
4. Collagen type 4
5. CT, echo, etc.
Further, the general observations were conducted on the ages, sexes, clinical
recordings until the dosages of Yojyo Hen Shi Ko, terms of dosages, daily dosages,
effects, and side effects etc.
Conclusion:
For almost all 195 cases of the various types of the patients of the liver
diseases, the ALT(GPT) level has decreased down to the normal level in 10-14 days.
As the future research issues, the following issues are to be examined.
1. Side effects
2. Combination dosages of Yojyo Hen Shi Ko with Interferon, specifically, before
and after the dosages for specially the patients of hepatitis type C.
3. Study for biomicroscopy cases
